AR056509A1 - Agentes terapeuticos - Google Patents
Agentes terapeuticosInfo
- Publication number
- AR056509A1 AR056509A1 ARP060103991A ARP060103991A AR056509A1 AR 056509 A1 AR056509 A1 AR 056509A1 AR P060103991 A ARP060103991 A AR P060103991A AR P060103991 A ARP060103991 A AR P060103991A AR 056509 A1 AR056509 A1 AR 056509A1
- Authority
- AR
- Argentina
- Prior art keywords
- imidazol
- dichlorophenyl
- methyl
- piperidin
- phenyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- -1 Ethanesulfonic acid 4- [2- (2,4-dichlorophenyl) -5-methyl-4- (piperidin-1-ylcarbamoyl) -imidazol-l-yl] phenyl ester Chemical class 0.000 abstract 11
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- WSQBYDZANOSFBX-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-5-methyl-n-piperidin-1-yl-1-[4-(4,4,4-trifluorobutoxy)phenyl]imidazole-4-carboxamide Chemical compound C=1C=C(OCCCC(F)(F)F)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl WSQBYDZANOSFBX-UHFFFAOYSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical class CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 abstract 1
- 150000002823 nitrates Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Procesos para preparar dichos compuestos, su utilizacion en el tratamiento de la obesidad, trastornos siquiátricos y neurologicos, a método para su utilizacion terapéutica y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto seleccionado entre: Piperidin1-ilamida del ácido l-(4-benciloxifenil)-2-(2,4-diclorofenil)-5-metil-lH-imidazol-4-carboxílico; 4-[2-(2,4-diclorofenil)-5-metil-4-(piperidin-1-ilcarbamoil)-imidazol-l-il]feniléster del ácido etansulfonico; 4- [2-(2,4-diclorofenil)-5-metil-4-(piperidin-l-ilcarbamoil)-imidazol-l-il]feniléster del ácido propan-1-sulfonico; 4-[2-(2,4-diclorofenil)-5-metil-4-(piperidin-l-ilcarbamoil)-imidazol-l-il]feniléster del ácido butan-1-sulfonico; piperidin-1-ilamida del ácido 2-(2,4-diclorofenil)-5-metil-l-[4-(4,4,4-trifluorbutoxi)fenil]-lH-imidazol-4-carboxílico; 4-[2-(2,4-diclorofenil)-5-metil-4-(piperidin-1-ilcarbamoil)imidazol-l-il]feniléster del ácido 3,3,3-trifluorpropan-1-sulfonico; 4-[2-(2,4- diclorofenil)-5-metil-4-(piperidin-1-ilcarbamoil)imidazol-1-il]feniléster del ácido 4,4,4-trifluorbutan-1-sulfonico; 4-{2-(2,4-diclorofenil)-5-metil-4-[(piperidin-1-ilamino)carbonil]-lH-imidazol-1-il}fenil tiofen-2-sulfonato; 4-{2-(2,4-diclorofenil)- 5-metil-4-[(piperidin-l-ilamino)carbonil]-lH-imidazol-l-il}fenilpiridin-3-sulfonato; 4-{2-(2,4-diclorofenil)-5-metil-4-[(piperidin-1-ilamino)carbonil]-lH-imidazol-1-il}fenilpiridin-3-sulfonato; 4-{2-(2,4-diclorofenil)-5-metil-4-[(piperidin-l- ilamino)carbonil]-lH-imidazol-l-il}fenil 3-metilbutan-1-sulfonato; 4-{2-(2,4-diclorofenil)-5-metil-4-[(piperidin-1-ilamino)carbonil]-lH-imidazol-1-il}fenil 3,3-dimetilbutan-l-sulfonato; 4-[2-(2,4-diclorofenil)-5-metil-4-({[5-(trifluormetil)piridin-2- il]amino}carbonil)-lH-imidazol-l-il]fenil 3,3,3-trifluorpropan-l-sulfonato; y 4-[2-(2,4-diclorofenil)-5-metil-4-({[5-(trifluormetil)piridin-2-il]amino}carbonil)-lH-imidazol-1-il]fenil 3-metilbutan-1-sulfonato; en la forma de una sal metansulfonato (sal mesilato), una sal hemi-1,5-naftalendisulfonato, una sal del ácido hemi-1,2-etandisulfonico, una sal clorhidrato, una sal etilsulfonato, una sal nitrato, una sal sulfato o una sal hidrogeno sulfato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0518817.2A GB0518817D0 (en) | 2005-09-15 | 2005-09-15 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056509A1 true AR056509A1 (es) | 2007-10-10 |
Family
ID=35248813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103991A AR056509A1 (es) | 2005-09-15 | 2006-09-13 | Agentes terapeuticos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090005415A1 (es) |
| EP (1) | EP1940803A1 (es) |
| JP (1) | JP2009507907A (es) |
| KR (1) | KR20080048063A (es) |
| CN (1) | CN101263122A (es) |
| AR (1) | AR056509A1 (es) |
| AU (1) | AU2006290553A1 (es) |
| BR (1) | BRPI0615939A2 (es) |
| CA (1) | CA2621408A1 (es) |
| EC (1) | ECSP088366A (es) |
| GB (1) | GB0518817D0 (es) |
| NO (1) | NO20080969L (es) |
| RU (1) | RU2008110916A (es) |
| TW (1) | TW200804301A (es) |
| UY (1) | UY29790A1 (es) |
| WO (1) | WO2007031720A1 (es) |
| ZA (1) | ZA200801744B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US11986602B2 (en) * | 2016-05-31 | 2024-05-21 | Abiomed, Inc. | Catheter of a heart pump shaped for anatomic fit |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| HN2002000266A (es) * | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
| JP2006525320A (ja) * | 2003-05-08 | 2006-11-09 | アステラス製薬株式会社 | Ｃｏｘ阻害剤 |
| JP4177435B2 (ja) * | 2004-04-03 | 2008-11-05 | アストラゼネカ アクチボラグ | 治療薬 |
| EP1833802A2 (en) * | 2004-12-23 | 2007-09-19 | AstraZeneca AB | 1,2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands |
-
2005
- 2005-09-15 GB GBGB0518817.2A patent/GB0518817D0/en not_active Ceased
-
2006
- 2006-09-12 EP EP06779372A patent/EP1940803A1/en not_active Withdrawn
- 2006-09-12 CN CNA2006800339512A patent/CN101263122A/zh active Pending
- 2006-09-12 RU RU2008110916/04A patent/RU2008110916A/ru not_active Application Discontinuation
- 2006-09-12 AU AU2006290553A patent/AU2006290553A1/en not_active Abandoned
- 2006-09-12 US US12/066,946 patent/US20090005415A1/en not_active Abandoned
- 2006-09-12 WO PCT/GB2006/003356 patent/WO2007031720A1/en not_active Ceased
- 2006-09-12 JP JP2008530599A patent/JP2009507907A/ja active Pending
- 2006-09-12 KR KR1020087008738A patent/KR20080048063A/ko not_active Withdrawn
- 2006-09-12 CA CA002621408A patent/CA2621408A1/en not_active Abandoned
- 2006-09-12 BR BRPI0615939-7A patent/BRPI0615939A2/pt not_active Application Discontinuation
- 2006-09-13 AR ARP060103991A patent/AR056509A1/es unknown
- 2006-09-14 UY UY29790A patent/UY29790A1/es not_active Application Discontinuation
- 2006-09-15 TW TW095134216A patent/TW200804301A/zh unknown
-
2008
- 2008-02-22 ZA ZA200801744A patent/ZA200801744B/xx unknown
- 2008-02-26 NO NO20080969A patent/NO20080969L/no not_active Application Discontinuation
- 2008-04-14 EC EC2008008366A patent/ECSP088366A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1940803A1 (en) | 2008-07-09 |
| GB0518817D0 (en) | 2005-10-26 |
| WO2007031720A1 (en) | 2007-03-22 |
| ECSP088366A (es) | 2008-05-30 |
| AU2006290553A1 (en) | 2007-03-22 |
| KR20080048063A (ko) | 2008-05-30 |
| US20090005415A1 (en) | 2009-01-01 |
| TW200804301A (en) | 2008-01-16 |
| BRPI0615939A2 (pt) | 2012-12-18 |
| CA2621408A1 (en) | 2007-03-22 |
| JP2009507907A (ja) | 2009-02-26 |
| RU2008110916A (ru) | 2009-10-20 |
| CN101263122A (zh) | 2008-09-10 |
| UY29790A1 (es) | 2007-04-30 |
| NO20080969L (no) | 2008-04-11 |
| ZA200801744B (en) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056509A1 (es) | Agentes terapeuticos | |
| CA2555331A1 (en) | Therapeutic agents | |
| AU2007316605B2 (en) | 1,2,4-triazole derivatives as sigma receptor inhibitors | |
| UA90160C2 (ru) | Фунгицидная смесь для борьбы с фитопатогенными грибами, средство и способ борьбы, посевной материал, применение соединений для получения средства | |
| NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| PE20210402A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| NZ595035A (en) | Substituted diazole and triazole compounds and compositions and methods of use | |
| IL281196A (en) | Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[ 7]Anolene-2-carboxylate | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| MX2009005357A (es) | Derivados de hidantoina usados como inhibidores de metaloproteinasas de matriz. | |
| MY143599A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| PE20001493A1 (es) | Derivados de acido pirazolcarboxilico, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| WO2007017416A3 (de) | Fungizide mischungen enthaltend substituierte 1-methylpyrazol-4-ylcarbonsäureanilide | |
| PT968206E (pt) | Derivados n-heterocíclicos como inibidores de nos | |
| AU2008323526A1 (en) | Indole compounds and methods for treating visceral pain | |
| TW200621154A (en) | Fungicidal compositions | |
| RU2009149696A (ru) | 5-замещенные индазолы в качестве ингибиторов киназы | |
| NZ593594A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| PE20110930A1 (es) | 3,5-bis(3,4-dihidroxifenil)-1,2,4-triazol y la composicion que lo comprende | |
| RU2011134868A (ru) | N-замещенные насыщенные гетероциклические сульфоновые соединения с активностью агонистов рецептора св2 | |
| JP2016534143A5 (es) | ||
| PE20081169A1 (es) | Compuestos tipo pirazol y triazol sustituidos como inhibidores de ksp | |
| WO2011072207A1 (en) | Azocyclic inhibitors of fatty acid amide hydrolase | |
| CA2669311A1 (en) | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | |
| NZ594108A (en) | Benzimidazole compounds useful as inhibitors of Histone Deacetylase (HDAC) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |